Erik Tucker

Portland, OR, United States of America

Erik Tucker

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 4.4

ph-index = 7

Forward Citations = 118(Granted Patents)


Company Filing History:


Years Active: 2012-2024

Loading Chart...
Loading Chart...
15 patents (USPTO):

Title: The Innovative Journey of Erik Tucker: Pioneering Antibody Inventions

Introduction: Erik Tucker, a prolific inventor based in Portland, Oregon, has made significant contributions to the field of biomedicine through his groundbreaking work in developing antibodies for inhibiting thrombosis while preserving hemostasis.

Latest Patents: Erik Tucker's latest patents include "Antibodies capable of binding to the coagulation factor XIa and uses thereof" and "Antibodies against factor XI and uses thereof." These inventions focus on novel binding molecules, particularly antibodies, that target Factor XI to inhibit thrombus formation effectively.

Career Highlights: With an impressive total of 14 patents to his name, Erik Tucker has demonstrated his expertise in the field of biotechnology. He has notably been associated with renowned institutions such as Oregon Health & Science University and Vanderbilt University, where his innovative research has paved the way for advancements in thrombosis-related treatment.

Collaborations: Throughout his career, Erik Tucker has collaborated with esteemed peers such as Andras Gruber and David Gailani. Together, they have synergized their skills and knowledge to push the boundaries of antibody technology, leading to the development of impactful solutions for combating thrombosis.

Conclusion: Erik Tucker's inventive spirit and dedication to improving healthcare outcomes shine through his remarkable portfolio of patents. His visionary work in the realm of antibody innovations underscores his commitment to addressing critical medical challenges, and his collaborations have further enriched the field of biomedicine. Erik Tucker stands as a true trailblazer in the journey towards enhancing patient care and advancing medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…